Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM2 | O94759 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22710277 | 1.00 | TRPM2 (0.34) | TRPM2TSHRMAPK1POLBKDM4E | |
| SCHEMBL21420072 | 1.00 | TRPM2 (0.34) | TRPM2TSHRMAPK1POLBKDM4E | |
| SCHEMBL21420081 | 0.84 | MAPK1 (0.35) | TRPM2TSHRMAPK1POLBKDM4E | |
| SCHEMBL21420082 | 0.84 | MAPK1 (0.35) | TRPM2TSHRMAPK1POLBKDM4E | |
| SCHEMBL25615667 | 0.83 | TRPM2 (0.35) | TRPM2TSHRMAPK1POLBKDM4E | |
| SCHEMBL14487698 | 0.83 | TRPM2 (0.35) | TRPM2TSHRMAPK1POLBKDM4E | |
| SCHEMBL21407673 | 0.83 | TRPM2 (0.35) | TRPM2TSHRMAPK1POLBKDM4E | |
| SCHEMBL24194064 | 0.73 | TRPM2 (0.33) | TRPM2TSHRMAPK1POLBCYP2C9 | |
| SCHEMBL14487871 | 0.73 | TRPM2 (0.40) | TRPM2TSHRMAPK1POLBCYP2C19 | |
| SCHEMBL15708479 | 0.73 | TRPM2 (0.35) | TRPM2TSHRMAPK1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220009904-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2022-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009904-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | TRPM2 4495/4885TSHR 3048/4885MAPK1 3385/4885 |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | TRPM2 4495/4885TSHR 3048/4885MAPK1 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.